Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent clinical progress in Gaucher disease.

Gregory A Grabowski1

  • 1The Children's Hospital Research Foundation, Cincinnati Children's Hospital Medical Center, and the Department of Pediatrics of the University of Cincinnati, Cincinnati, Ohio 45229-3039, USA. greg.grabowski@chmcc.org

Current Opinion in Pediatrics
|July 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges in Gaucher disease: Perspectives from an expert panel.

Molecular genetics and metabolism·2025
Same author

Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.

Human molecular genetics·2024
Same author

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, <i>GBA1</i> mutation-associated pathologies and diseases.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

Therapies for lysosomal storage diseases: Principles, practice, and prospects for refinements based on evolving science.

Molecular genetics and metabolism·2022
Same author

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease.

Cells·2021
Same author

Gaucher disease: Basic and translational science needs for more complete therapy and management.

Molecular genetics and metabolism·2021
Same journal

For health, for beauty, or both? navigating trends as adolescent clinicians.

Current opinion in pediatrics·2026
Same journal

Childhood sleep disorders: practical management for the pediatrician.

Current opinion in pediatrics·2026
Same journal

Advanced therapies in management of pediatric inflammatory bowel disease.

Current opinion in pediatrics·2026
Same journal

Artificial intelligence in pediatric endoscopy for hereditary polyposis syndromes: promises and challenges.

Current opinion in pediatrics·2026
Same journal

Hormonal acne therapies in pediatrics.

Current opinion in pediatrics·2026
Same journal

Clinical implementation of artificial intelligence in adolescent mental healthcare.

Current opinion in pediatrics·2026
See all related articles

Early detection and genetic insights are crucial for managing Gaucher disease variants. Pediatricians play a key role in diagnosis and treatment decisions for Gaucher disease, guiding patient care.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Gaucher disease management has advanced with enzyme replacement therapy, highlighting the need for early diagnosis.
  • Understanding genotype/phenotype correlations aids in distinguishing nonneuronopathic (type 1) and neuronopathic (types 2 and 3) Gaucher disease variants.

Purpose of the Study:

  • To review clinical advances in Gaucher disease, focusing on detection, prediction, and treatment of variant phenotypes.
  • To emphasize the importance of early diagnosis and intervention in preventing severe manifestations of Gaucher disease.

Main Methods:

  • Review of current literature on Gaucher disease diagnosis and treatment.
  • Analysis of genotype/phenotype correlations for prognostic guidance.
  • Examination of therapeutic goals for assessing treatment responses.

Related Experiment Videos

Main Results:

  • Enzyme therapy necessitates early diagnosis to prevent organomegaly, growth/pubertal issues, and bone disease.
  • Genotype/phenotype distinctions (type 1 vs. types 2/3) offer prognostic insights.
  • Assessing therapeutic and palliative responses requires defined goals for all Gaucher disease types.

Conclusions:

  • Pediatricians are central to clinical and genetic decision-making in Gaucher disease management.
  • Early detection of at-risk children presents a significant challenge for pediatric and metabolic physicians.